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Hemodynamic classifications of aortic valve stenosis (AS) have important 
prognostic implications. In normal flow state, severe AS is defined as peak aortic 
velocity ≥ 4.0 m/s, mean transaortic gradient (MG) ≥ 40 mmHg, and aortic valve 
area (AVA) < 1.0 cm2. However, numerous studies have shown that severe AS 
(based on AVA < 1.0 cm2) with low gradient (MG < 40 mmHg) is prevalent due 
to low flow state, in the setting of reduced and preserved left ventricular ejection 
fraction (LVEF). Thus, the hemodynamic classifications of AS with AVA < 1.0 
cm2 were expanded to include the transvalvular flow state and pressure gradients. 
These flow-gradient patterns include normal flow/very high gradient, normal 
flow/high gradient, low flow/high gradient, low flow/low gradient with reduced 
LVEF, low flow/low gradient with preserved LVEF, and normal flow/low gradi-
ent. Among these, the low-gradient AS subgroups are challenging, particularly 
to differentiate true-severe AS (where aortic valve replacement is necessary) and 
pseudo-severe AS (where conservative management is recommended). Additional 
diagnostic studies such as dobutamine stress echocardiography and/or cardiac 
computed tomography, as well as other parameters such as projected AVA and/
or valvuloarterial impedance may be helpful. This chapter will review diagnostic 
approaches and prognostic implications of different AS subtypes.
Keywords: aortic stenosis, classification, echocardiography, hemodynamics,  
low flow, prognosis
1. Introduction
Aortic valve stenosis (AS) is the most common valvular heart disease in developed 
countries. When symptomatic, AS is known to have significant morbidity and mortal-
ity. While the prevalence of AS is expected to rise with the aging population, there is no 
pharmacological treatment option to prevent its progression at this time [1, 2]. Aortic 
valve replacement (AVR) is the only treatment demonstrated to improve survival and 
symptoms [3, 4]. Therefore, in the management of patients with AS, it is essential to 
accurately diagnose the disease severity and determine the proper timing of surgical 
referral. According to the ACC/AHA guidelines, AVR is class I indication for patients 
with symptomatic severe AS with high transaortic mean gradient (MG) ≥ 40 mmHg 
and left ventricular (LV) ejection fraction (LVEF) < 50% and/or who are undergoing 
another surgery [5]. Over the past decade, challenges due to discrepancies with grading 
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AS severity and the necessity of integrating the valve gradient with flow patterns 
were recognized when a significant subset of patients were found to have small AVAs 
suggestive of severe AS with lower gradients despite preserved LVEF [6]. As a result, 
under the umbrella of severe AS (based on AVA < 1.0 cm2), a new hemodynamic 
classification of AS was proposed which can be categorized into six subgroups based 
on LV flow state [normal flow (NF) vs. low flow (LF)] and pressure gradient [very 
high gradient (VHG) vs. high gradient (HG) vs. low gradient (LG)]. These six flow-
gradient patterns (NF/VHG, NF/HG, LF/HG, LF/LG with reduced LVEF, LF/LG with 
preserved LVEF, and normal NF/LG) have shown to represent distinct pathophysi-
ologic types of severe AS with different clinical outcomes (see Table 1).
2. Natural history of AS
AS is a progressive valvular heart disease with gradual valvular narrowing 
resulting in LV outflow tract (LVOT) obstruction over time. Degenerative calcific 
AS is the most common type of this disease process and predominantly affects the 
elderly. With this condition, there is a long latent period during which the patient is 
asymptomatic although there is progression of obstructive physiology at the aortic 
valve and LV pressure overload. Survival in asymptomatic patients undergoing con-
servative management with watchful waiting is not statistically different from age- 
and gender-matched controls [7]. However, once symptoms of angina, syncope, or 
heart failure develop, there is a very rapid decline. Patients with AS who develop 
angina have a 5-year survival, syncope 3-year survival, and heart failure, the most 
ominous of all, 2-year survival (see Figure 1) [8, 9]. Thus, when symptoms are 
corroborated by established echocardiographic criteria for severe AS, some form 
of intervention is required because these individuals only have a 3-year survival of 
about 25%. In severe asymptomatic AS, the rate of symptom onset is higher when 
significant calcification of the aortic valve is present and in older patients [7]. Other 
factors demonstrated to predict symptom onset and surgical outcome include brain 
natriuretic peptide (BNP) [10]. While the risk of sudden death is a major concern in 
patients with asymptomatic AS undergoing conservative management, numerous 
studies have shown that the risk is very low, <1% per year [7, 11, 12].
Over the years, there has been marked decrease in the operative risk of 
AS. Furthermore, while prior studies have shown rather benign prognosis of 
asymptomatic severe AS patients, suggesting that delay in surgery can be safe until 
the development of symptoms, there is controversy as to the optimal timing of AVR 
Table 1. 
Hemodynamic classification of severe aortic stenosis (AVA < 1.0 cm2).
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and whether elective or early intervention during the asymptomatic stage might be 
better long term. At present, the surgical mortality for AVR is <2% for severe AS 
in patients with New York Heart Association (NYHA) functional class I or II heart 
failure, whereas this risk is significantly higher with class III or IV [13]. Thus, even 
though the patient may be asymptomatic, AS severity can progress and cause LV 
dysfunction during the conservative management period and significantly increase 
the surgical risk [14]. Furthermore, there is concern regarding the development of 
significant LV myocardial hypertrophy and irreversible myocardial fibrosis due to 
pressure overload which may result in persistent postoperative diastolic dysfunction 
and heart failure, even if AVR is successful [15, 16]. However, a general recommen-
dation cannot be made at this time due to insufficient evidence to justify the benefit 
of AVR in asymptomatic patients to outweigh the risks of surgery and complica-
tions related to prosthesis long-term. However, those patients who may benefit from 
early surgical intervention should be identified through risk stratification [17]. 
Over the past decade, transcatheter aortic valve replacement (TAVR) has emerged 
as an alternative treatment strategy for symptomatic severe AS patients who are not 
suitable or prohibitive for surgical AVR (SAVR) [18, 19] or at high risk for surgery 
[20, 21]. This technology then expanded to benefit patients with intermediate 
operative risk, where TAVR using a self-expanding prosthesis was noninferior to 
SAVR at 24 months follow-up [22]. More recently, TAVR using a balloon-expandable 
SAPIEN 3 system in low-risk patients was shown to be superior to SAVR based on 
a composite of death, stroke, and rehospitalization at 1-year follow-up, despite 
excellent surgical results [23]. Long-term follow-up studies are underway to help 
determine the true therapeutic impact of TAVR vs. SAVR.
3. Severe AS: definition and rate of hemodynamic progression
AS severity quantitation is based on the degree of LVOT obstruction caused by 
progressive narrowing of the aortic valve orifice. Echocardiography with Doppler 
evaluation is the main modality for diagnosing AS. Traditionally, hemodynamic 
severity of AS has been described based on peak aortic jet velocity (Vmax), MG, 
and AVA. According to the 2014 ACC/AHA guidelines, severe AS is defined as 
Vmax ≥ 4.0 m/s, MG ≥ 40 mmHg, and AVA < 1.0 cm
2 [24]. The rate of hemodynamic 
Figure 1. 
Natural history of aortic stenosis. A long, latent, asymptomatic period is present followed by a very rapid decline 
in survival with the onset of symptoms of angina, syncope, and/or heart failure in severe AS patients [8].
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progression in AS is highly variable. The average rate of progression was reported 
as increase in Vmax by 0.3 m/s/year and MG by 7 mmHg/year and decrease in AVA 
by 0.1 cm2/year [11]. Studies have shown that the strongest predictors of outcomes 
in AS were severity of the aortic valve obstruction. During a follow-up period 
of 2 years, progression of symptoms requiring AVR was about 80% for patients 
with Vmax > 4.0 m/s vs. 35% with Vmax of 3.0–4.0 m/s and 15% for patients with 
Vmax < 3.0 m/s. MG and AVA, other parameters of stenosis severity, were also strong 
predictors of patient outcomes [25].
4. Discrepancies with echocardiographic criteria for grading AS
Echocardiography is the current standard modality for evaluating AS severity. 
However, challenges due to inconsistencies between measurements of the MG and 
the calculated AVA in patients with normal systolic function were noted (see Figure 2). 
This finding was attributed primarily to differences in stroke volume and flow  
across the aortic valve. While it seems possible that discrepancies can occur when 
the cardiac output is low from reduced LVEF, inconsistent measurements in patients 
with preserved LVEF were observed. Another potential explanation for the discrep-
ancies was that effective valve area derived by Doppler echocardiography is often 
smaller than the anatomic valve area measured during cardiac catheterization or by 
planimetry or at autopsy. So while the initial guidelines for determining AS severity 
were based on invasive measurements (reflecting the anatomic valve area), echo-
cardiographic Doppler measurements are currently used to make clinical decisions 
for AS patients still based on the original anatomic valve area criteria. Thus, based 
on AVA, it is possible that more patients may be categorized as having severe AS 
Figure 2. 
Comparison of AVA vs. MG in AS patients with preserved LVEF. The predicted values from the Gorlin 
equation and the fitted curve of the study cohort are shown. The quadrants depict severe AS cutoff points based 
on the guidelines, and the percentages represent patients per quadrant. Thirty percent of the severe AS patients 
were diagnosed based on AVA, but not by MG [26].
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relative to the peak flow velocity and MG. Therefore, some authors have suggested 
that AVA cutoff value for severe AS be changed to 0.8 cm2 [26].
There are other potential etiologies of discrepant AVA and MG measurements in the 
setting of preserved LVEF which also need to be taken into consideration. First, techni-
cal errors need to be excluded. For example, LVOT diameter measurement may be 
inaccurate, and/or LVOT velocity time integral may be underestimated due to misplace-
ment of the pulsed wave Doppler sample in the LVOT, leading to the underestimation of 
the stroke volume and the AVA. Second, patients with small body habitus and small LV 
dimensions could have lower stroke volume and lower transaortic gradient. Therefore, 
additional diagnostic studies such as dobutamine stress echocardiography (DSE), 
calcium scoring using multi-detector computed tomography (MDCT), and/or BNP 
may be necessary to corroborate AS severity and guide management strategy.
5. Hemodynamic classifications of AS
In patients with AVA < 1 cm2, there are six flow-gradient patterns: NF/VHG, 
NF/HG, LF/HG, LF/LG with reduced LVEF, LF/LG with preserved LVEF, and NF/
LG. VHG is defined as MG ≥ 60 mmHg, and HG is defined as MG ≥ 40 mmHg; 
stroke volume index (SVI) of normal flow is ≥35 ml/m2. Low flow is defined 
as SVI < 35 ml/m2. Low gradient is defined as MG < 40 mmHg. LF/LG AS with 
reduced LVEF is present when the gradient is low, the flow is low, and the LVEF is 
abnormal (<50%). LF/LG AS with preserved LVEF is present when the gradient is 
low and the flow is low but the LVEF is normal (>50%) (see Table 1).
5.1 High-gradient AS
Severe VHG AS (Vmax ≥ 5.0 m/s) has significantly worse prognosis than severe 
HG AS (Vmax ≥ 4.0 m/s) [3], so we acknowledge VHG AS as a separate entity from 
HG AS. However, most studies assessing AS severity using the new classification 
system combined NF/VHG and NF/HG as one entity under the subgroup of NF/
HG. Thus, we will characterize these two groups together and highlight some of the 
relevant findings for VHG AS.
5.1.1 Normal flow/very high gradient or high gradient
NF/VHG AS pattern is defined as AVA < 1.0 cm2, MG ≥ 60 mmHg, Vmax ≥ 5.0 m/s, 
and LVEF ≥ 50% with SVI ≥ 35 ml/m2. NF/HG AS is defined as MG ≥ 40 mmHg and 
Vmax ≥ 4 m/s with the same criteria for AVA, LVEF, and SVI as NF/VHG. Patients 
with these two flow-gradient patterns are the most prevalent (up to 70%) of all the 
AS groups. These patients tend to have more severe valvular stenosis suggesting more 
prolonged exposure to the progressive disease process. Compared with the NF/LG 
group, there is preservation of LV longitudinal function. However, these patients have 
higher BNP level and lower cardiac-event free survival [27].
When evaluating AS severity, Vmax is an important parameter which closely 
correlates with outcome. One study assessing the outcome of asymptomatic patients 
with very severe AS found that the higher the velocity, the lower the event-free 
survival with most patients experiencing some event within 3 years (see Figure 3). 
Patients with Vmax ≥ 5 m/s were symptomatic at presentation. Furthermore, 
asymptomatic patients with Vmax ≥ 5.5 m/s were highly likely to develop rapid onset 
of symptoms [3]. A landmark study evaluating the rate of hemodynamic progres-
sion and predictors of outcome in asymptomatic AS patients demonstrated that 
when Vmax exceeds 4 m/s, virtually all patients become symptomatic in 5 years. 
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The velocity traditionally reflects the chronicity of the degenerative process. Vmax 
between 3 and 4 m/s were also found to be not benign, and only 20% of patients 
remained asymptomatic over 5 years. Only when Vmax was <3 m/s, there was an 85% 
chance that the patient will remain asymptomatic for 5 years [11] (see Figure 4).
MG is another well-recognized parameter for defining AS severity. One study 
assessed the prognostic impact of MG on all-cause mortality in severe AS with 
preserved LVEF. They found that MG > 60 mmHg at baseline was associated with 
greater risk of all-cause mortality than lower values, thereby justifying a separate 
hemodynamic classification. The higher MG also reflected the chronicity of the 
disease process [28] (see Figure 5).
AVA < 1.0 cm2 also correlated with poor outcome compared to moderate or 
mild categories. More severe AVAs carried worse prognosis, and like Vmax and MG, 
they reflected disease chronicity. While the rate of progression is highly variable, 
the often quoted number is 0.1 cm2/year [29] (see Figure 6). However, when Vmax 
was high or very high (4–6 m/s), there was no significant difference in the outcome 
based on the calculated AVA [3].
According to the current ACC/AHA guidelines, symptomatic NF/HG and NF/
VHG severe AS patients have a class I indication for AVR. When asymptomatic, 
these AS subgroups are recommended to undergo further risk stratification.
5.1.2 Low flow/high gradient
This pattern of AS is defined as AVA < 1.0 cm2, MG ≥ 40 mmHg, and 
LVEF ≥ 50% with SVI < 35 ml/m2. The prevalence of this AS subtype is much less 
(8%) [30]. These patients have LV remodeling with reduced longitudinal function 
despite preserved LVEF. As a consequence, LV output is reduced with resultant 
lower than expected MG. LF/HG AS patients have shown to have high BNP, and 
their prognosis is similar or worse than those with NL/HG AS. When symptomatic, 
these patients have better survival with AVR [27, 31].
Figure 3. 
Event-free survival with very severe AS. Kaplan-Meier estimates demonstrate that maximum aortic jet velocity 
closely correlates with outcome, with higher the velocity, the lower the event-free survival [3].
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5.2 Low-gradient AS
Three types of low-gradient severe AS have been described based on the LVEF 
and the flow state. LF/LG AS with reduced LVEF (<50%) is present when there 
is LV systolic dysfunction with reduced stroke volume in the setting of severe AS 
which results in decreased transvalvular velocity/gradient. If the LVEF is normal 
(≥50%), the stroke volume index (SVI) helps determine the presence of LF/LG 
AS with preserved LVEF (if the SVI is low, <35 ml/m2) or NF/LG AS (if the SVI is 
normal, ≥35% ml/m2) [32] (see Table 2).
5.2.1 Low flow/low gradient with reduced LVEF
This AS subtype, also known as “classical” LF/LG AS, is defined as 
AVA < 1.0 cm2, MG < 40 mmHg, SVI < 35 ml/m2, and LVEF < 50%. LF/LG AS with 
Figure 4. 
Effect of Vmax on outcomes in asymptomatic AS. Cox regression analysis demonstrating event-free survival in 
asymptomatic AS patients categorized by initial peak aortic jet velocity [11].
Figure 5. 
Impact of MG on outcomes in severe AS. Kaplan-Meier estimates of survival based on MG [28].
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reduced LVEF accounts for about 5–10% of the AS population [33, 34] and has the 
worst outcome among all the AS categories [30, 33, 34]. The low flow state is usu-
ally associated with LV systolic dysfunction either from pressure overload due to the 
underlying severe AS or cardiomyopathy of another etiology.
In order to differentiate true-severe AS from pseudo-severe AS, low-dose 
DSE is the initial recommended study to determine whether there is normal 
flow reserve (an increase in stroke volume of >20%) or diminished flow reserve 
(see Figure 7).  Patients with normal flow reserve may have true-severe AS 
(MG ≥ 40 mmHg with AVA < 1.0 cm2 at any stage of DSE) which requires AVR 
or pseudo-severe AS (MG < 40 mmHg with AVA > 1.0 cm2) where medical ther-
apy is recommended [32, 35]. In patients where the increase in stroke volume 
with DSE is <20% but >15% and MG is <40 mmHg, the definitive diagnosis of 
AS severity may remain questionable. In this case, the projected AVA calculation 
using normal flow rate may be beneficial where a value <1.0 cm2 is suggestive 
of true-severe AS [36] (see (Eq. (1)). However, if the stroke volume increase is 
<15%, further evaluation beyond DSE is often required, and calcium quantifica-
tion of the aortic valve using MDCT is helpful in confirming the AS severity. 
The cutoff values for true-severe AS is >1200 AU in women and >2000 AU in 
men [37, 38].
Figure 6. 
(A) Adjusted event-free survival based on AVA. (B) Cumulative hazard of death based on AVA [29].
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Valvuloarterial impedance (Zva) is an index to evaluate global LV hemodynamic 
load using Doppler echocardiography (see Eq. (2)). Zva > 5 has been shown to 
predict adverse outcomes in patients with AS and LV dysfunction. Since AS is a 
disease of the elderly, in addition to valvular stenosis, vascular stiffness due to vari-
ous factors including age and hypertension may be present. As a result, the LV may 
be subject to a double afterload, known as global LV afterload or Zva. In general, 
higher Zva is associated with worse outcome. However, since Zva is a flow-depen-
dent parameter, this index may be less reliable in low flow states since small changes 
in stroke volume can produce large changes in Zva [39].
Table 2. 
Subclassification of low gradient AS.
Figure 7. 
Algorithm for diagnosing LF/LG AS with reduced LVEF. AS, aortic stenosis; AVA, aortic valve area; MG, 
mean gradient; LVEF, left ventricular ejection fraction; SV, stroke volume; AV, aortic valve; MDCT, multi-
detector computed tomography.
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Two-dimensional and three-dimensional transesophageal echocardiography 
may also be beneficial for confirming AS severity via direct visualization of the 
aortic valve anatomy and physiology.
In general, LF/LG AS has the worst prognosis compared to the other catego-
ries in part because the severity of AS is often under-recognized and surgical 
treatment is delayed. Patients with LF/LG AS with reduced LVEF have higher 
adverse event rates and mortality than LF/LG AS with preserved LVEF. The 
operative risk is also high in this AS subgroup. However, AVR has shown to 
have significant survival benefit compared to patients undergoing conservative 
management [40]. Furthermore, TAVR in LF/LG AS with reduced LVEF has 
demonstrated to have significant survival benefit compared with standard medi-
cal therapy in patients who are not suitable for surgery and similar outcomes 
compared with SAVR for patients at high surgical risk [41]. According to the 
ACC/AHA guidelines, true-severe LF/LG AS with reduced LVEF has a class IIa 
indication for AVR [42] (see Table 3).
5.2.2 Low flow/low gradient with preserved LVEF
LF/LG AS with preserved LVEF, also described as “paradoxical” LF/LG AS, is 
defined as AVA < 1.0 cm2, AVA indexed < 0.6 cm2/m2, MG < 40 mmHg, SVI < 35 ml/m2, 
and LVEF ≥ 50%. This AS pattern has generated much controversy among investiga-
tors. Studies have reported that low flow state is present in about 30% of AS patients 
with normal LVEF [31, 43–46]. This AS subgroup accounts for about 15–35% of the 
symptomatic and 5–10% of the asymptomatic AS patients [30]. The classic character-
istics described with this AS subtype are small LV cavity size with marked concentric 
hypertrophy, myocardial fibrosis, restrictive diastolic physiology, reduced LV lon-
gitudinal systolic function, and increased global LV afterload resulting in reduced 
SVI and worse outcome [6, 31, 47]. Other factors associated with this pattern include 
women, older age, systemic and/or pulmonary hypertension, atrial fibrillation, mitral 
regurgitation, and right ventricular dysfunction [27, 46]. Some studies have shown that 
these patients have one of the worst prognoses as the disease severity is often under-
recognized and surgery is delayed. This pattern has shown to have better outcomes than 
LF/LG AS with reduced LVEF but worse outcomes than moderate AS, HG AS, and NF/
LG AS [31, 41, 48]. The likelihood of remaining alive in 3 years without AVR has been 
reported about five fold lower than normal flow state [43].
Table 3. 
Recommendations for aortic valve replacement in LF/LG AS.
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When evaluating patients with this AS entity, it is essential to first exclude 
potential technical errors which may affect the gradient, stroke volume, and AVA 
measurements. Next, an integrated approach assessing the different criteria to 
support severe AS needs to be evaluated. These parameters include clinical charac-
teristics such as physical examination suggestive of severe AS, patient symptoms, 
and the presence of hypertension. Potential etiologies of low flow state need to be 
considered. Qualitative imaging analyses such as the presence of left ventricular 
hypertrophy and LV strain measurements should also be assessed. Once LF/LG AS 
with preserved LVEF status is confirmed, quantitation of aortic valve calcification 
using MDCT may be helpful in differentiating true-severe vs. pseudo-severe AS 
[35, 49] (see Figure 8). One small study showed that low-dose DSE may be useful in 
confirming the diagnosis with this entity [50].
According to the ACC/AHA guidelines, LF/LG AS with preserved LVEF has a 
class IIa indication for AVR, if clinical, anatomic, and hemodynamic data support 
that the patient’s symptom is from the obstructive pathophysiology of the aortic 
valve [42] (see Table 3). One randomized trial data showed significant survival 
benefit after TAVR compared to standard medical treatment or similar clinical 
outcomes vs. SAVR [41]. In patients with greater degree of LV myocardial fibrosis, 
more advanced stage of diastolic dysfunction and low SVI demonstrated worse 
outcomes after TAVR [51, 52].
In contrast to the findings described above, some other investigators have 
shown differing results for this AS entity. In one prospective study with a large 
number of patients with asymptomatic AS, there was no difference between the 
moderate stenosis and the low-gradient “severe” AS groups in terms of valve-
associated events, major cardiovascular events, or cardiac death, even when 
the groups were subcategorized into low flow and normal flow states [53]. 
Figure 8. 
Algorithm for diagnosing LF/LG AS with preserved LVEF. LF, low flow; LG, low gradient; AS, aortic stenosis; 
AVA, aortic valve area; MG, mean gradient; LVEF, left ventricular ejection fraction; SVI, stroke volume 
index; AV, aortic valve; MDCT, multi-detector computed tomography.
Aortic Stenosis - Current Perspectives
12
Another large study demonstrated that patients with LF/LG AS with preserved 
LVEF had better spontaneous survival than the patients with HG severe AS, 
and the results are unaffected by flow states. Furthermore, the patients with 
LF/LG AS with preserved LVEF progressed to develop HG AS over time, and in 
all patients who showed a reduction in transvalvular gradients over time, this 
decrease was associated with reduction in LVEF [54]. Another study showed 
that patients with severe LF/LG AS with preserved LVEF had similar outcomes 
as patients with mild to moderate AS, and there was no significant benefit of 
AVR in this group [55]. However, a comparison of two studies by Hachicha 
et al. [31] and Jander et al. [53] showed that there were some differences 
between the study group findings which may, at least in part, have contributed 
to the differing outcomes. Some investigators have proposed for reducing the 
AVA cutoff value for severe AS closer to ≤0.8 cm2 to avoid overestimation of AS 
severity [56].
5.2.3 Normal flow/low gradient
This AS pattern is defined as AVA < 1.0 cm2, AVA indexed < 0.6 cm2, 
MG < 40 mmHg, and LVEF ≥ 50% with SVI ≥ 35 ml/m2. NF/LG AS has shown 
to be present in about one third of AS patients [30], and some studies have 
suggested that this AS pattern may be due to marked reduction in transaortic 
gradient from systemic hypertension and decreased aortic compliance [57, 
58]. Patients with NL/LG AS are reported to have less severe disease than the 
other AS categories with lower BNP and preserved LV longitudinal function 
[35]. In terms of diagnosis, technical measurement errors need to be excluded, 
and aortic valve calcium scoring using MDCT may be beneficial to further 
determine the AS severity [38]. According to the 2017 European Association 
of Cardiovascular Imaging and the American Society of Echocardiography 
Recommendations, however, this entity is considered to be due to measurement 
errors or the consequence of inconsistent cutoff values for transaortic velocity/
gradient and AVA [35]. Some studies have supported this thought as patients 
in the NF/LG AS subgroup demonstrated the same outcome as patients with 
moderate AS [59].
There are no particular recommendations for this subgroup in the current guide-
lines, and AVR should only be considered in symptomatic patients with confirmed 
severe AS. One study showed survival benefit in these patients [43], while another 
study showed no difference in survival in patients who underwent early AVR 
compared to conservative management [60].
Projected AVA calculation
  Projected AVA = AVArest +  (  ∆ AVA ___________∆ Q ) ∗  (250 − Qrest) 
  ∆ AVA = AVA peak − AVA rest = Change in AVA at rest and at peak DSE 
  ∆ Q = Q peak − Q rest = Change in Q at rest and at peak DSE (1)
Projected AVA at a normal flow rate (250 ml/s) <1.0 cm2 suggests severe AS.
AVArest, aortic valve area at rest; DSE, dobutamine stress echocardiography; 
AVApeak, aortic valve area at peak; Qrest, stroke volume at rest; Qpeak, stroke 
volume at peak DSE.
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Valvuloarterial impedance calculation
  Zva =  
Systemic Arterial Pressure + Mean Pressure Gradient
    ________________________________________ 
Stroke Volume Index
 
                        Zva = Valvuloarterial Impedence                                                        (2)
6. Conclusions
The different hemodynamic categories of severe AS have shown to have varying 
clinical outcomes. Low flow state has exhibited the worst prognosis due to intrinsic 
myocardial dysfunction and/or under-recognition of the disease severity resulting 
in inappropriate delay in AVR. Low-gradient AS with low flow state is of particular 
challenge for clinical decision-making, especially when differentiating true-severe 
AS (where AVR may be beneficial) vs. pseudo-severe AS (where conservative medi-
cal management is appropriate). In LF/LG AS with reduced LVEF, DSE is beneficial 
for the confirmation of AS severity and risk stratification. In the setting of partial 
or no flow reserve, projected AVA and/or calcium scoring with MDCT may be 
useful to guide management. LF/LG AS with preserved LVEF is an entity where 
the natural history and the pathophysiology are not well understood. There has 
been much controversy and differing schools of thought around this AS subgroup. 
Numerous studies have shown that LF/LG AS with preserved LVEF is associated 
with poor prognosis, and therefore, careful evaluation and identification of these 
patients are necessary to ensure proper management. Calcium quantification using 
MDCT has shown to be the preferred technique for confirming AS severity with this 
subgroup. However, other investigators have reported that this AS entity represents 
moderate AS with no significant difference in outcomes between the groups. These 
discrepant findings may be resolved based on more randomized studies with large 
cohorts and with the application of more advanced diagnostic imaging techniques 
capable of overcoming the limitations of the currently available technology to better 
assess AS severity. In symptomatic high-gradient severe AS, regardless of the flow 
state, AVR is the only treatment option that has demonstrated to improve symptoms 
and survival. In asymptomatic high-gradient severe AS, regardless of the flow state, 
the current guidelines recommend watchful waiting and conservative management, 
although controversy exists about the optimal timing of intervention.
Over the years, the operative risk for SAVR for severe AS has significantly 
decreased, and TAVR has emerged as a promising alternative treatment for these 
patients with different operative risk profiles—high, intermediate, and more 
recently low risk. Recent data have supported that TAVR is superior or noninferior 
to SAVR in the treatment of severe AS and long-term follow-up assessment will 
better validate the true comparison between the two approaches and determine 
the optimal treatment strategy. As the TAVR technology continues to advance, the 
next generations of bioprostheses will be introduced which may further improve 
outcomes. Therefore, it is vital to accurately diagnose AS severity and identify those 
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